Utarini 2021.

Study characteristics
Methods	Status: completed Aim: to assess the efficacy of deployments of Ae aegypti mosquitoes infected with the wMel strain of Wolbachia in reducing the prevalence of VCD in Yogyakarta, Indonesia. Study type: cRCT Study dates: 8 January 2018 to 5 May 2020 Country, location: Indonesia, urban Unit of allocation: cluster Number of units: 24 Length of follow‐up: 27 months
Participants	Number of participants: 6306; 2905 intervention, 3401 control Method of recruitment: screening at primary care clinics Loss to follow‐up: 222 intervention, 222 control (could not be contacted) Age (median): 11.6 years (IQR 7.0 to 21.1), 22% aged < 15 years Sex (% female): 48.7 Socio‐economic status: N/I
Interventions	Wolbachia species: wMel Mosquito species: Ae aegypti Mosquito life stage at release: egg Strategy: population replacement Number of deployments: 9–14 rounds per cluster (mean 22,000–34,000 mosquitoes released per round) Timing of deployments: every 2 weeks between March and December 2017 Location of deployments: mosquito release containers placed outside houses, protected from sun and rain, at 1 or 2 randomly selected locations within each 50 × 50 m2 grid across the intervention area Aimed % vector population replacement: deployments stopped in a cluster when wMel prevalence was > 60% in the mosquito population for > 3 weeks Achieved % vector population replacement: monthly median cluster‐level wMel prevalence 95.8% (IQR 91.5 to 97.8) Field monitoring strategy: prevalence of wMel in Ae aegypti population measured weekly using BG Sentinel traps for adult mosquito collection, screened for wMel Wolbachia by qualitative PCR Taqman assay Co‐interventions: routine mosquito control measures, N/I
Outcomes	Primary outcome Symptomatic VCD of any severity caused by any DENV serotype Secondary outcomes Symptomatic VCD caused by each of the 4 DENV serotypes (DENV‐1, DENV‐2, DENV‐3, and DENV‐4) Relative abundance of Ae aegypti and Ae albopictus (see Tantowijoyo 2022 under Utarini 2021) Insecticide resistance phenotypes of Ae aegypti (see Tantowijoyo 2022 under Utarini 2021) Hospitalization within 21 days All‐cause mortality
Notes	Funding source: Tahija Foundation, Wellcome Trust, and the Bill and Melinda Gates Foundation.

BG: Biogents; cRCT: cluster‐randomized controlled trial; DENV: dengue virus; IQR: interquartile range; N/I: no information; PCR: polymerase chain reaction; VCD: virologically confirmed dengue.